TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01038778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG-PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET/CT
Study: NCT02432794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delay phenomenon by arteriographic approach
Description: we improve the microvascularization of the gastric fundus occluding the right and left gastric artery, and splenic artery two weeks before surgery by arteriography
Study: NCT00436306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Intervention
Description: Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer-based contraceptive information
Description: Contraceptive method information is provided on a computer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based contraceptive information
Description: Contraceptive method information is provided on a computer.
Study: NCT01274637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin Sodium
Description: 5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.
Study: NCT03317990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NeuroSAFE procedure
Description: When the prostate is removed from within the patient as it is disconnected from its attachments. The specimen will then be painted (right=blue, left =black) by the operating surgeon and delivered expediently to the pathologist who will perform frozen section analysis of the painted areas. The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade. The tissue sample will be snap frozen and embedded in OCT. If a significant positive margin (on more than one section from one side or in a single section but greater than or equal to 3mm) is reported by the pathologist, the entire neurovascular bundle on the affected side will be removed and sent for formal pathological examination.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard RARP
Description: Patients will undergo the standard intervention - RARP without NeuroSAFE Frozen section analysis
Study: NCT03533075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teachable Moment Brief Intervention
Description: Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt
Study: NCT02316197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2490484A (M3814)
Description: Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2490484A (M3814)
Description: Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2490484A (M3814)
Description: Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2490484A (M3814)
Description: Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2490484A (M3814)
Description: Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2490484A (M3814)
Description: Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2490484A (M3814)
Description: Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
Study: NCT03500757

Intervention type: DEVICE
Intervention: HoloLens
Description: use the HoloLens to evaluate new 3D holographic guidance and navigation for percutaneous ablation of solid tumors
Study: NCT02684006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab (MSB0010718C)
Description: IV treatment Avelumab administered at 10 mg/kg IV every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: Oral treatment Axitinib given 5 mg PO BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
Study: NCT01046916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-700
Description: TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule
Study: NCT01262313

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lifestyle Counseling
Description: Participants in the intervention group will attend an 8-week group intervention discussing Healthy Creations lifestyle changes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Participants in the intervention group will attend an 8-week group intervention discussing Healthy Creations lifestyle changes.
Study: NCT04438928

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elevit Pregnancy 2nd & 3rd Trimester
Description: Once daily micronutrient plus DHA supplementation (Multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules)

Intervention type: OTHER
Group type: OTHER
Intervention: Non-Supplement
Description: Control study group of pregnant women non-supplemented with multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules
Study: NCT01720095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niaspan
Study: NCT02354638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco users
Description: Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Description: Pharmacotherapy will also be prescribed as per the need assessment consisting of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks
Study: NCT03444142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide LAR
Description: 2 mg, once weekly subcutaneously before breakfast during 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: .75 mg once weekly subcutaneously before breakfast during 4 weeks.
Study: NCT03887091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postwire
Description: Postwire© is a web-based, video platform
Study: NCT03957538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality angiogram experience video
Description: The VR video is watched via the VR headset, and describes the pre- procedural and procedural experience. Concurrent audio will be provided through earplugs to compete the patients' immersive experience. The video was written and directed by the team, and care has been taken to ensure that the same procedural information is contained within both the British Heart Foundation cardiac catheterisation video and of VR immersive video. Filming was performed within the cardiac catheterisation labs at our tertiary centre using the professional services of Orchard Media (Cardiff, UK). The investigators utilized real physicians and nurses to re-enact a typical day for a mock patient undergoing an uncomplicated procedure. There is also a short explanation of the procedure and animations explaining technical aspects of the procedure contained within the VR video.
Study: NCT02665728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI400 Laxative
Study: NCT00567788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost-Bimatoprost
Description: latanoprost 0.005% once daily followed by bimatoprost 0.03%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoporost-Latanoprost
Description: bimatoprost 0.03% once daily followed by latanoprost 0.005%
Study: NCT03768739

Intervention type: PROCEDURE
Intervention: Fiberoptic Endoscopic Evaluation of Swallowing
Description: This procedure involves a flexible laryngoscope that contains a light source and video camera on the end through the open passages of your nose and to the back of the throat in order to visualize the swallowing mechanism.
Study: NCT03997903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: The starting dose for subjects will be 340 mg/m2/day with a maximum dose of 600 mg daily.~Patients will receive Imatinib orally once daily for 6 months.
Study: NCT03296163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB02 (Bevacizumab Biosimilar Drug)
Description: 15 mg/kg IV every 3 weeks on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Avastin®
Description: 15 mg/kg IV every 3 weeks on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin Area under the curve (AUC) 6 IV every 3 weeks on Day 1 for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin Area under the curve (AUC) 6 IV every 3 weeks on Day 1 for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 6 cycles
Study: NCT04055194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid tablets
Description: Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
Study: NCT04295889

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Approach A (PeeSpot urine collection device).
Description: The participant will receive the PeeSpot urine collection device (Hessels+Grob B.V., Deventer, The Netherlands), which consists of a holder containing a urine collection pad (consisting of hygroscopic material containing). The holder can be placed back into the tube and can be easily sent to the laboratory by mail. In this urine, albumin, creatinine, and the ACR will be measured in the laboratory of the Amphia hospital.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Approach B (ACR | EU Test kit).
Description: The participant will receive the ACR \| EU test kit (Healthy.io Ltd, Tel-Aviv- Yafo, Israel), which consists of a urine test strip, a urine cup, a color calibrator and instruction to download a smartphone application. The participants have to download the smartphone application according to the instructions included in the kit. Results will be directly shown to the participant in the app.
Study: NCT04600960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: The subjects will initiate treatment with 75 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 75 mg daily. Subjects whose platelet count ≤100×109/L，the eltrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of eltrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of eltrombopag to 25mg once every other day during the treatment period, eltrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off eltrombopag if the platelet is greater than 50×109/L.
Study: NCT03844451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: At the conclusion of the procedure, liposomal bupivacaine will be administered as a V2 nerve block.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine and Epinephrine
Description: At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine and Epinephrine
Description: At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.
Study: NCT01584947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine lozenge taken 3 times a day for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lozenge taken three times a day for two weeks
Study: NCT05684679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentive spirometer plus Chest physiotherapy
Description: Incentive spirometer was given to IS group. However, a conventional chest physiotherapy was given to both groups in the optimal position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercise plus Chest physiotherapy
Description: Diaphragmatic breathing exercise was given to DBE group. In addition, a conventional chest physiotherapy was given in the optimal position.
Study: NCT03380468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin plus pemetrexed
Description: cisplatin 75mg/m2 iv; pemetrexed 500mg/m2 iv
Study: NCT03178656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: continuous application of the drugs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: curative resection
Study: NCT02676544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere microspheres
Description: This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.
Study: NCT04040101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone-based balance training system
Description: use smartphone application to training balance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: smartphone-based balance training system
Description: use smartphone application to training balance
Study: NCT02442817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: 12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: 12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.
Study: NCT04582422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Touch Therapy
Description: During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation
Study: NCT01422434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90105 = calcipotriol + betamethasone dipropionate
Description: Applied once daily for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dovonex® = calcipotriol
Description: Applied twice daily for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rinderon® - DP = betamethasone dipropionate
Description: Applied once daily for 4 weeks.
Study: NCT02734017

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacist-led standardized medication review
Description: the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacist-led standardized medication review
Description: the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.
Study: NCT00703261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
Study: NCT03099655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Attain Stability Quad Left Ventricular Pacing Lead
Description: cardiac stimulation
Study: NCT01988337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin infiltration
Description: The study is a split-mouth design. One tooth with a proximal caries lesion will randomly receive the infiltrating resin (Icon) while the other will receive a placebo, according to the manufactures´ instruction for Icon. In short, teeth will be isolated with a rubber dam and the tooth surface cleaned with non-fluoride prophylactic paste and pumice. The Icon material will be applied following the manufacturer's instructions and light cured, followed by polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN). Subjects will be given a letter to take to their local dentist asking them not to treat the selected lesions without informing the investigator first.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mock treatment
Description: For the mock treatment the procedure will be identical to the Resin Infiltration intervention, with the exception that a placebo will be used. Essentially, syringes identical to the Icon materials will be supplied by DMG for the placebo procedure. The syringes will be filled with solutions having the same consistency and color as the Icon material.
Study: NCT03191435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training.
Description: Patients will perform the inspiratory muscle training using a moderate load of 30% of maximal inspiratory pressure (MIP 30%). The training will be conducted at home in a period of 30 minutes, 7 times a week, during 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed. Furthermore, load in the device (powerbreathe) will be adjusted for the individual to use next week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inspiratory muscle
Description: Patients will perform the inspiratory muscle training using a very low load of 2% of maximal inspiratory pressure (MIP 2%). The training will be conducted at home in a period of 30 minutes, 7 times a week, in the course of 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed.
Study: NCT02886494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAC treatment
Description: BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched vehicle
Description: BAC matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks